Table 2.
Univariate logistic regression analysis of clinicopathological variables associated with CK19 status in hepatocellular carcinoma.
| Variable | OR (95% CI) | p value |
|---|---|---|
| Gender (male vs. female) | 1.22 (0.24-6.26) | 0.81 |
| Age (<60 vs. ≥60 years) | 0.49 (0.15-1.61) | 0.24 |
| HBV infection (no vs. yes) | 0.57 (0.16-2.01) | 0.38 |
| Cirrhosis status (no vs. yes) | 1.48 (0.55-3.99) | 0.44 |
| ALBI grade (grade 1 vs. grade 2) | 0.63 (0.23-1.71) | 0.37 |
| MELD score (<9 vs. ≥9) | 1.22(0.24-6.26) | 0.81 |
| Tumor size (<5 vs. ≥5 cm) | 1.60 (0.59-4.36) | 0.35 |
| AST (<40 vs. ≥40 U/L) | 1.00 (0.32-3.06) | 1.00 |
| ALT (<40 vs. ≥40 U/L) | 1.54 (0.54-4.36) | 0.42 |
| PT (<12.1 vs. ≥12.1 sec) | 0.55(0.17-1.77) | 0.32 |
| Platelet (<125 vs. ≥125 × 109/L) | 0.60 (0.19-1.90) | 0.38 |
| Serum AFP (<400 vs. ≥400 ng/mL) | 5.38 (1.88-15.34) | <0.001∗ |
| Serum CA 19-9 (<34 vs. ≥34 U/mL) | 0 (0-Inf) | 0.99 |
| Serum CEA (<5 vs. ≥5 ng/mL) | 0.45 (0.05-3.74) | 0.46 |
∗ p < 0.05. AFP: alpha fetoprotein; ALBI: albumin-bilirubin grade; ALT: alanine aminotransferase; AST: aspartate aminotransferase; CA 19-9: carbohydrate antigen 19-9; CEA: carcinoembryonic antigen; CI: confidence interval; HBV: hepatitis B virus; MELD score: Model for End-Stage Liver Disease score; OR: odds ratio; PT: prothrombin time.